A journal article was submitted detailing a single-center retrospective database analysis study which evaluated the impact of the baseline estimated glomerular filtration rate (egfr) on clinical and angiographic outcomes and long-term in-stent restenosis (isr) rates in patients undergoing elective carotid artery stenting (cas) procedures.Medtronic¿s spider fx distal embolic protection device was used when crossing the lesion.Medtronic¿s protégé rx self-expanding stents the endovascular cas procedure.477 cas procedures were evaluated for enrolment in the study.33 patient deaths are reported during the 3-year follow-up period resulting from exclusion from the study.Other reasons for exclusion included patients lost to follow-up.The study population remained at 405, in which 38 protégé rx stents were implanted.Pre-dilation was performed in 40 patients, and post dilation performed in 93.6% pf patients.In-stent restenosis is reported in 44 patients throughout the follow-up period.The overall death rate was reported as 7.5% of the study group over the three years.There is no established or suspected causal relationship between the device(s) and the death events.
|
Medtronic is submitting this report to comply with fda reporting regulations under 21 cfr parts 4 and 803.This report is based upon information obtained by medtronic, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Medtronic has made reasonable efforts to obtain more complete information and has provided as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any ¿defects¿ or has ¿malfunctioned¿.These words are included in the fda 3500a form and are fixed items for selection created by the fda to categorize the type of event solely for the purpose of regulatory reporting.Medtronic objects to the use of these words and others like them because of the lack of definition and the connotations implied by these terms.This statement should be included with any information or report disclosed to the public under the freedom of information act.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.A good faith effort will be made to obtain the applicable information relevant to the report.If information is provided in the future, a supplemental report will be issued.
|